Targeted delivery of proteins to the intestines for treating inflammatory bowel diseases
Platform technology for targeted delivery of proteins to the intestines
This study is working on a new way to deliver medicine directly to the intestines to help people with inflammatory bowel diseases like ulcerative colitis, making treatments more effective and easier on the body.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vitakey, INC. NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10922023 on NIH RePORTER |
What this research studies
This research focuses on developing a new technology for the targeted delivery of therapeutic proteins specifically to the intestines, which is crucial for treating inflammatory bowel diseases (IBD) like ulcerative colitis. By improving the local delivery of biologics, the research aims to enhance treatment efficacy while minimizing systemic side effects and reducing the overall cost of therapy. The approach addresses significant challenges such as the inactivation of biologics by digestive processes and aims to create a more effective treatment option for patients suffering from IBD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inflammatory bowel diseases, particularly those experiencing ulcerative colitis.
Not a fit: Patients with non-inflammatory bowel conditions or those who do not have access to biologic therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with inflammatory bowel diseases.
How similar studies have performed: Other research has shown promise in targeted delivery systems for biologics, indicating potential for success with this novel approach.
Where this research is happening
Washington, United States
- Vitakey, INC. — Washington, United States (Active)
Researchers
- Principal investigator: Anselmo, Aaron C — Vitakey, INC.
- Study coordinator: Anselmo, Aaron C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.